Navigation Links
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Date:3/31/2008

ID-TLR) rates were comparable, at 3.8 percent for the XIENCE V (PROMUS) Stent and 6.8 percent for the TAXUS Stent (p=0.33). Major adverse cardiac events (MACE) rates comprised of cardiac death, all MI and ID-TLR were also comparable, at 6.6 percent for the XIENCE V (PROMUS) Stent and 11.0 percent for the TAXUS Stent (p=0.31).

Stent thrombosis rates at two years using the Academic Research Consortium (ARC) definite/probable definition were low for both the XIENCE V (PROMUS) Stent (0.9%) and the TAXUS Stent (1.4%). Angiographic outcomes showed numerically equivalent late loss, with 0.33 mm for XIENCE V (PROMUS) and 0.34 mm for TAXUS (p=0.60). In-stent binary restenosis rates at two years were also comparable for the XIENCE V (PROMUS) Stent and the TAXUS Stent (2.1% vs. 2.9%, p=1.0).

"Boston Scientific's two DES platforms - the TAXUS and PROMUS Stents - both performed extremely well in the SPIRIT II Trial out to two years," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "The data, once again, demonstrated impressive safety and efficacy profiles with low stent thrombosis rates and similar clinical outcomes. We look forward to future data from the SPIRIT Clinical Trial Program as well as from our PROENCY Registries in Europe and the United States - the first to observe different 'Olimus-eluting coronary stents in a real-world setting."

In February, Boston Scientific announced that the first patient had been enrolled in its PROENCY (PROMUS(TM), ENdeavor(R) and CYpher(R)) European Registry. The registry will collect real-life clinical outcome data for the PROMUS Stent and compare them with data from Johnson & Johnson's Cypher(R) Sirolimus-Eluting Stent and Medtronic's Endeavor(R) Zotarolimus-Eluting Stent in patients in routine clinical practice. A U.S. PROENCY Registry is expected to begin enrolling patients in July and complete enrollment by the end of 2008.

The XIENCE(TM) V (PROMUS) Stent is currently pending approval by
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
3. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
4. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
9. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
10. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
11. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015 E-QURE Corp (OTCQB: EQUR), ... live at VirtualInvestorConferences.com on July 9, 2015. ... http://tinyurl.com/e-qure-presentation This will be a ... ask the company questions in real-time - both in ... trade booth." If attendees are not able to join ...
(Date:7/6/2015)... -- Celtaxsys, Inc., a clinical stage pharmaceutical development company ... orphan inflammatory disease indications, announced today that it has ... (FDA) to begin a Phase 2 clinical trial of ... patients in the US. The regulatory submissions to the ... be filed soon after. This groundbreaking clinical study, testing ...
(Date:7/6/2015)... , July 6, 2015  OncoSec Medical Inc. ... intratumoral cancer immunotherapies, today announced the appointment of ... of Vice President of Market Development, effective July 6, ... for evaluating, designing, and executing on the company,s market ... "I,m very excited to welcome Joann to the ...
Breaking Medicine Technology:E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is ... 2014-2015 Post Graduate Teaching Award on behalf of the department of Family Practice. , ... exciting field to be practicing in. The technology is changing so rapidly and we ...
(Date:7/6/2015)... ... July 06, 2015 , ... Longevity, ... has partnered with Woodbridge Walk-In Urgent Care to offer on-site health screenings. These ... medical conditions. Screenings are affordable and accurate and run about an hour long ...
(Date:7/6/2015)... ... July 06, 2015 , ... Health care systems and genomics projects have generated ... to access and use this “Big Data” to improve health and cut costs is ... of the Mount Sinai Health System in New York City. Physicians will have these ...
(Date:7/6/2015)... ... July 06, 2015 , ... In a split second, breaking a ... their risk of having a fracture through the bone health screenings conducted by American ... “We are participating because our residents need this information to remain independent and strong ...
(Date:7/6/2015)... ... July 06, 2015 , ... World renowned Los ... to achieve their ideal appearance through comprehensive treatment solutions. Individuals that want to make ... doctor and receive a plan that resolves each of their needs. , "Anytime ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:National Bone Health Screening and Awareness Day 2Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2
... 11 They feature real patients, real stories and ... campaign titled "Real Patients, Real Stories" won Platinum in ... event held in Chicago this fall. , Baylor teamed ... the non-traditional spots. The documentary-style ads feature actual patients ...
... 41.9% with the greatest reduction in child casualties, according to ... Road traffic injuries are a leading cause of death ... important contribution to public health burdens over the coming decades, ... UK has a comparatively good road injury record, with among ...
... cells can lose their epithelial receptors, a process that enables ... from The University of Texas M. D. Anderson Cancer Center. ... Antonio Breast Cancer Symposium. Levels of these circulating tumor ... or its metastases - have been used to monitor and ...
... that could prevent another blood clot, study finds , FRIDAY, ... survivors don,t take medications that can reduce their risk of ... is caused by blocked blood flow in the brain. Several ... stroke. These include blood thinners (antithrombotic medications), of which aspirin ...
... , , , GAINESVILLE, Fla., Dec. ... studied the amazing regenerative power of salamanders, trying to ... usually leave humans and other mammals paralyzed -- or ... Institutes of Health Grand Opportunity grant of $2.4 million, ...
... , PHILADELPHIA, Dec. 11 Autism research ... one of the top ten medical breakthroughs of 2009 by Time ... Time cited the largest-ever genetic study of autism spectrum disorders (ASDs), ... led by Hakon Hakonarson, M.D., Ph.D., director of the Center for Applied ...
Cached Medicine News:Health News:Baylor Health Care System's Patient Testimonial Ad Campaign Wins National Award 2Health News:More 20 mph zones in London would prevent 100 killed or seriously injured casualties each year 2Health News:Novel detection method unmasks circulating breast cancer cells 2Health News:Novel detection method unmasks circulating breast cancer cells 3Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 2Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 3Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 4Health News:Autism Research at the Children's Hospital of Philadelphia Is Among Time Magazine's Top 10 Medical Breakthroughs 2
... Portable Slit-Lamp. Rechargeable, cordless ... for any purpose , Easy selection ... blue filter , Extra-bright halogen lamp ... main and extra ,power pack , ...
The PillCam™ ESO video capsule is specifically designed to view the inner lining of the Esophagus. The capsule is equipped with miniature cameras on both ends and is about the size of a multi-v...
World's first commercially available vacuum assisted biopsy device for MRI....
... Now you can perform stereotactic, ultrasound ... the convenience of your office. Use the ... safer, easier and more clinically advanced method ... its best for the women who trust ...
Medicine Products: